IQVIA Holdings Inc. $IQV Shares Bought by Taikang Asset Management Hong Kong Co Ltd

Key Points

• Taikang Asset Management Hong Kong Co Ltd increased its stake in IQVIA Holdings Inc. by 9.3%, purchasing an additional 2,519 shares and bringing its total holdings to 29,463 shares valued at approximately $5.19 million.
• Analysts have a consensus rating of “Moderate Buy” for IQVIA, with a target price of $228.62 and the stock receiving 17 buy ratings and 6 hold ratings from research analysts.
• In recent insider trading, Eric Sherbet, an insider, sold 5,800 shares for around $1.1 million, resulting in a 17.59% decrease in his holding, while company insiders own only 1.60% of the total shares.

Taikang Asset Management Hong Kong Co Ltd boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 29,463 shares of the medical research company's stock after acquiring an additional 2,519 shares during the quarter. Taikang Asset Management Hong Kong Co Ltd's holdings in IQVIA were worth $5,194,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Sowell Financial Services LLC acquired a new position in IQVIA during the first quarter worth $305,000. Mather Group LLC. increased its position in shares of IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after buying an additional 350 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of IQVIA by 11.6% during the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after buying an additional 566 shares during the last quarter. Park Avenue Securities LLC boosted its position in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after buying an additional 1,562 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after acquiring an additional 3,398 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on IQV shares. UBS Group upped their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Truist Financial increased their target price on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Barclays boosted their price target on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Finally, Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $228.62.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Trading Down 0.0%

Shares of IQV stock traded down $0.07 on Thursday, reaching $188.73. 1,161,570 shares of the stock were exchanged, compared to its average volume of 1,323,966. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The stock has a market cap of $32.08 billion, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 2.07 and a beta of 1.30. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a 50 day moving average of $176.32 and a two-hundred day moving average of $167.99.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.